Loading...

DMRA DAMORA THERAPEUTICS INC Management Changes 8-K Filing

DMR

DMR

DAMORA THERAPEUTICS INC

(DMRA)

2026 8-K

Management Changes

Accounting Firm Change

Management Changes

Name Change Announcement

Stock Offering Announcement

Management Change

Investor Conference Update

Management Changes

Correction Filing

Merger Completion

Board Appointment

Asset Acquisition

Nasdaq Compliance

Annual Meeting Results

Deficiency Letter from Nasdaq

Positive trial results for ...

Clinical Trial Update

Restructuring Plan and Stra...

Phase 2b GALACTIC-1 Trial R...

Annual Meeting Results

FDIC Takeover of Silicon Va...

Financial Update

External Links:

Damora Therapeutics, Inc. appointed Jennifer Jarrett as CEO effective March 30, 2026, and three directors resigned effective March 23, 2026, with no disagreements reported. Jennifer Jarrett will earn a base salary of $695,000, and her severance package includes 12 months of salary and other benefits upon termination without cause.

AI Assistant

DAMORA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.